Here’s some info on the program.
In order to reduce the risk of coronary events and prevent the complications of cardiovascular disease in patients with hypercholesterolemia, clinicians need to be familiar with current guideline recommendations and be able to interpret them within the context of the latest clinical trial data. Clinicians need to recognize patient groups in which treatment beyond statins may be needed to optimize lipid-related CV risk.
Even though statins are first line therapy for the treatment of hypercholesterolemia, a significant number patients cannot tolerate them or have a suboptimal response to them. Thus, clinicians must be familiar with the safety, efficacy, and application of PCSK9 inhibitors in reducing LDL-C and cardiovascular risk in patients with hypercholesterolemia. According to the CDC, public and medical education is needed to prevent and reduce the risk of coronary heart disease and death in patients who are at high cardiovascular risk.
[lms_course category=”diabetes” column=”4″ num_fetch=”2″ thumbnail_size=”small” orderby=”date” order=”desc” pagination=”yes” ]